Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives Positive Feedback from the US FDA on Phase III Study Protocol for its Treatment of dRTA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives MHRA Approval to Market Sibnayal\u2122 (ADV7103) in the UK for the Treatment of DRTA","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Advicenne Announces Commercialization Agreement With FrostPharma AB for Sibnayal\u2122 in the Nordic region","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal\u2122) and announces Leadership Changes to support Commercialisation","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Advicenne","sponsor":"Avanzanite Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal\u00ae For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Advicenne","sponsor":"Avanzanite Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avanzanite Bioscience Expands Partnership with Advicenne in Additional European Countries","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Advicenne

    Menu

    Advicenne

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Advicenne

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avanzanite Bioscience Expands Partnership with Advicenne in Additional European Countries

              Details:

              Under the partnership, Avanzanite gains commercialization and distribution rights into three additional European countries, for Sibnayal (potassium citrate and potassium bicarbonate), the first approved medicinal product in Europe for distal Renal Tubular Acidosis.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Avanzanite Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advicenne

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal® For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece

              Details:

              Sibnayal (potassium citrate) is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Avanzanite Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advicenne

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advicenne Announces Commercialization Agreement With FrostPharma AB for Sibnayal™ in the Nordic region

              Details:

              Under the terms of the agreement, FrostPharma will receive exclusive marketing rights to Sibnayal™ for the treatment of dRTA. Advicenne will receive a transfer price for the sale of its product and royalties for an amount significantly higher than 50% of future sales.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: FrostPharma AB

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advicenne

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advicenne Receives MHRA Approval to Market Sibnayal™ (ADV7103) in the UK for the Treatment of DRTA

              Details:

              Sibnayal™ is a multi-particulate formulation in 2mm granules, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advicenne

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advicenne Receives Positive Feedback from the US FDA on Phase III Study Protocol for its Treatment of dRTA

              Details:

              Advicenne’s lead product, ADV7103, is developed as a multi-particulate formulation in 2mm microtablets, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients to ease its administration.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advicenne

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Advicenne Receives European Commission Approval to Market ADV7103 (Sibnayal™) and announces Leadership Changes to support Commercialisation

              Details:

              ADV7103/Sibnayal (potassium citrate) becomes the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

              Lead Product(s): Potassium Citrate,Potassium hydrogen carbonate

              Therapeutic Area: Nephrology Product Name: Sibnayal

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 03, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY